Psychoactive Drug Screening (PDSP)

NIMH PDSP的目的是为以下物质提供新的合成化合物和天然产物的筛选 可能被用作基础和临床研究的研究工具或探针，作为精神障碍的治疗剂， 以及正电子发射断层扫描(PET)、单光子发射计算机断层扫描(SPECT)和功能 用于脑功能成像的磁共振成像(FMRI)配体。 该程序主要用于筛选先前已被证明具有的化合物 与NIMH相关的药理、生化或行为活动，而不是为了大规模、随机的目的 筛选天然产物或组合库(例如，包含&gt；1000化合物的库)。然而， 可以对活性未知的合成或天然产物化合物的小型文库进行筛选 通过NIH资助的高通量筛选(HTS)或化学计划产生的Hit或Lead化合物。

The purpose of the NIMH PDSP is to provide screening of novel synthetic compounds and natural products for potential use as research tools or probes for basic and clinical research, as therapeutic agents for mental disorders, and as positron emission tomography (PET), single photon emission computed tomography (SPECT), and functional magnetic resonance imaging (fMRI) ligands for functional brain imaging. This program is primarily intended as a screen for compounds that have previously been shown to possess pharmacological, biochemical, or behavioral activities relevant to NIMH and not for the purpose of large-scale, random screening of natural products or combinatorial libraries (e.g., libraries containing >1000 compounds). However, screening maybe conducted on small libraries of synthetic or natural product compounds of unknown activity and on hit or lead compounds generated through NIH-funded high throughput screening (HTS) or chemistry programs.